| Phase 11 trial |
|
Phase 1
|
NCT05001516 |
Dec 2021 → Jan 2024 |
neoplasm |
Turning Point Therapeutics, Inc. |
Completed
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT05994001 |
Aug 2023 → May 2026 overdue |
biliary tract cancer |
Shanghai Zhongshan Hospital |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05188664 |
May 2022 → Nov 2023 |
neoplasm |
LaNova Medicines Limited |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT05161390 |
Nov 2021 → Jan 2025 |
neoplasm |
LaNova Medicines Zhejiang Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07569068 |
Apr 2026 → Apr 2028 expected |
gastroesophageal adenocarcinoma |
Ruijin Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07108504 |
Aug 2025 → Aug 2026 overdue |
chemotherapy-induced toxicity, malignant pancreatic neoplasm |
Shanghai Zhongshan Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06519591 |
Feb 2025 → May 2026 overdue |
gastric cancer, peritoneal carcinomatosis |
Ruijin Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06587425 |
Jul 2024 → Jul 2025 overdue |
adenocarcinoma |
Shanghai Zhongshan Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05934331 |
Jul 2023 → Jul 2026 overdue |
digestive system cancer |
LaNova Medicines Zhejiang Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07385703 |
Apr 2026 → Oct 2028 expected |
adenocarcinoma |
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06351020 |
Jun 2024 → Nov 2026 expected |
gastric adenocarcinoma |
LaNova Medicines Zhejiang Co., Ltd. |
Active not recruiting
|
No outcome recorded
|